Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Matinas BioPharma Holdings, Inc.

Get SEC filing alerts via email and in your feed for Matinas BioPharma Holdings, Inc.

MTNB

Matinas BioPharma Holdings, Inc.

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings is a clinical-stage biopharmaceutical company developing lipid nanocrystal (LNC) platform-based therapies. Its lead product, MAT2203, is an oral antifungal designed to treat invasive fungal infections with improved safety and convenience. The company focuses on strategic partnerships, licensing, and advancing its pipeline through regulatory designations, targeting high-need markets such as invasive aspergillosis and cryptococcal meningitis.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Matinas BioPharma Holdings, Inc.

1
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $1.92 Million Net Loss in Q1 2026, Focuses on Partnerships

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $10.3 Million Net Loss and Pauses Development of MAT2203

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $1.5 Million Net Loss in Q3 2025, Sees Significant Reduction in R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $5.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $1.656 Million Net Loss in Q1 2025, Down from $5.824 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports $24.3 Million Net Loss and Workforce Reduction Amid Strategic Shift

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Matinas BioPharma Holdings, Inc. Matinas BioPharma Reports Financial Results, Sees Improvement in Losses and Cash Position

Via official filing (AI summary) | over 1 year ago | 0 comments